In the subsequent phase III randomized multicenter ASCEND-4 trial, treatment-naïve ALK-positive NSCLC patients were randomized to receive ceritinib or platinum-based chemotherapy until disease progression or unacceptable toxicity. This evidence concerns the gene ALK and non-small cell lung carcinoma.